Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Flublok Quadrivalent

            Therapeutic Area: Infections and Infectious Diseases Product Name: Flublok

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            Flublok has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency (MHRA) for immunisation against flu in this year’s seasonal flu programme to meet public health need.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DTaP-IPV

            Therapeutic Area: Infections and Infectious Diseases Product Name: Tetraxim

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2020

            Details:

            Tetraxim® (DTaP-IPV) is a 4-in-1 booster vaccine and the only inactivated poliomyelitis containing combination vaccine in India that has full-dose antigenic strength of Diphtheria, Tetanus and acellular Pertussis (whooping cough) for preschoolers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Meningococcal (Groups A, C, Y, W) Conjugate Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: MenQuadfi

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            The recommendation is supported by seven double-blind, randomized, multicenter Phase 2 and 3 clinical studies comparing MenQuadfi with other licensed combination vaccines, demonstrating a good safety profile and high immune response against all four serogroups.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Quadrivalent recombinant influenza vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Supemtek

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 22, 2020

            Details:

            Positive opinion based on clinical data demonstrating safety and efficacy of Supemtek® for adults aged 18 and older demonstrated in two Phase 3 randomized controlled trials involving more than 10,000 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Inactivated aluminum-adjuvanted JE vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: IXIARO

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: US Government

            Deal Size: $166.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement September 09, 2020

            Details:

            IXIARO® is the only JE vaccine approved by the U.S. Food and Drug Administration (FDA), having been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Miconazole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: m8 Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 18, 2020

            Details:

            m8 Pharmaceuticals and Vectans Pharma have signed an exclusive licensing agreement whereby m8 will have the rights to register and commercialize Loramyc® (miconazole) for Mexico and Brazil.